Bayer's SUNHARBO(r) (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination
November 09, 2026
November 09, 2026
WHIPPANY, New Jersey, Nov. 9 [Category: BizPharmaceuticals] -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, posted the following news:
* * *
Bayer's SUNHARBO(r) (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination With Antiplat . . .
* * *
Bayer's SUNHARBO(r) (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination With Antiplat . . .
